Cargando…
Sacubitril/valsartan-induced liver injury: A case report and literature review
Sacubitril/valsartan (Entresto) is the first drug approved for the treatment of symptomatic chronic heart failure with reduced ejection fraction in adult patients. There have been no reports of hepatotoxicity secondary to sacubitril/valsartan administration. Here, we report the first case of severe...
Autores principales: | Zhang, Ting, Cai, Jin-lian, Yu, Jie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10419355/ https://www.ncbi.nlm.nih.gov/pubmed/37565914 http://dx.doi.org/10.1097/MD.0000000000034732 |
Ejemplares similares
-
Sacubitril/Valsartan Conundrum
por: Somberg, John
Publicado: (2021) -
Hemolytic anemia in alcoholic liver disease: Zieve syndrome: A case report and literature review
por: Liu, Miao-Xia, et al.
Publicado: (2017) -
Nilotinib-induced liver injury: A case report
por: Tan, Youwen, et al.
Publicado: (2020) -
Pazopanib-induced severe acute liver injury: A case report
por: Choi, Jin-Wook, et al.
Publicado: (2021) -
Eligibility and Usage of Sacubitril/Valsartan in Korea
por: Kim, Jin-Jin, et al.
Publicado: (2019)